



**NETSCC, HTA** 

**24 February 2012** 

#### **Trial Protocol**

# Randomised controlled trial of a pedometer-based walking intervention with and without practice nurse support in primary care patients aged 45-74 years

# PACE-UP trial (Pedometer And Consultation Evaluation - Up) Unique trial identifier: HTA10/32/02

**Protocol version number 1.2** 

Proposed starting date: 01/03/2012 Proposed duration: 39 months

Proposed ending date: 31/05/2015

#### **Principal Investigator:**

Dr Tess Harris, Senior Lecturer in Primary Care & General Practitioner, Population Health Sciences & Education, St George's University of London, SW17 ORE. email: <a href="mailto:tharris@sgul.ac.uk">tharris@sgul.ac.uk</a>

## **Co-applicants:**

Professor Derek Cook, Professor of Epidemiology, Population Health Sciences & Education, St George's University of London, SW17 ORE.

Mrs Sally Kerry, Reader in Medical Statistics, Pragmatic Clinical Trials Unit, Barts & The London School of Medicine & Dentistry. E1 2AB.

Professor Christina Victor, Professor of Gerontology and Health Services Research, Brunel University, London UB8 3PH.

Dr Sunil Shah, Senior Lecturer in Public Health, Population Health Sciences & Education, St George's University of London, SW17 ORE.

Professor Steve Iliffe, Professor of Primary Care for Older People, University College, London, NW3 2PF.

Dr Michael Ussher, Reader in Health Psychology, Population Health Sciences & Education, St George's University of London, SW17 ORE.

Professor Julia Fox-Rushby, Professor of Health Economics, Health Economics Research Group, Brunel University, London UB8 3PH.

Dr Ulf Ekelund, Programme Leader Physical Activity Epidemiology, MRC Epidemiology Unit, University of Cambridge, CB2 OQQ.

Professor Peter Whincup, Professor of Epidemiology, Public Health Sciences & Epidemiology, St George's University of London, SW17 ORE.

#### **Collaborators:**

Dr David Finch, GP & Joint Medical Director NHS South West London Cluster,120, The Broadway, Wimbledon, London SW19 1RH.

Dr Judith Ibison, Senior Lecturer in Primary Care & General Practitioner, Population Health Sciences & Education, St George's University of London, SW17 ORE.

Dr Stephen DeWilde, Senior Lecturer in Primary Care & General Practitioner, Population Health Sciences & Education, St George's University of London, SW17 ORE

21/12/2011-TH Page 1 of 31

Dr Lee David, General Practitioner & Educational Company Director, 10 Minute CBT.

## **Clinical trial unit support:**

Pragmatic clinical trials unit (PCTU), Barts & The London School of Medicine & Dentistry, E1 2AB.

## **Sponsor:**

St George's University of London, Dr Lisa Clutterbuck, Clinical Research Governance Officer, Cranmer Terrace Tooting, London, SW17 ORE.

## **Funder:**

NIHR Health Technology Assessment Programme, NETSCC, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS.

## Signature Page

Chief Investigator: Dr Tess Harris		Date	
	Sally Kerry		
Trial statistician: Mrs Sally Kerry	0 0	Date	21/12/2011

Co	ntents	Page
1.	Summary	6
2.	Background and rationale	6
3.	Study objectives and purpose	11
4.	Study design	12
	Description of type of trial Schematic diagram of trial design, procedures and stages Primary and secondary endpoints / outcomes Methods and timing for assessing, recording and analysis of outcomes Measures taken to minimise / avoid bias	
5.	Participant selection	15
	Participant inclusion criteria Participant exclusion criteria Participant recruitment and number of participants Participant selection for the qualitative evaluation Participant withdrawal	
6.	Study procedures	16
	Informed consent procedures Randomisation procedures Baseline, 3 month & 12 month assessments Procedure for control group Nature of the intervention & components of the complex intervention Procedure for the pedometer plus written instructions group. Procedure for the pedometer plus practice nurse support group Procedure for qualitative study Procedure for health economic evaluation End of study definition Participant withdrawal Data collection and follow-up for withdrawn subjects	
7.	Safety	20
	Risks Adverse events & serious adverse events Causality Notification and reporting of adverse events and serious adverse events Retrospective data collection on adverse events Monitoring Annual safety reporting	

8.	Statistics	21
	Sample size	
	Anticipated recruitment	
	Statistical analysis	
	Stopping rules	
	Procedure for accounting for missing, unused and unexpected data	
9.	Data handling and record keeping	22
	Confidentiality & data protection	
	Maintenance of study documents	
	Record retention & archiving	
10.	Ethics, compliance & clinical governance	23
	Ethical considerations	
	Compliance	
	Clinical governance issues	
11.	Monitoring procedures	24
	Summary monitoring plan	
	Trial oversight committees: Trial Management Group, Trial Steering Committee	
	Before the start of recruitment	
	During the trial	
	At the end of the trial	
	Audit and inspection	
12.	Finance and insurance	25
	Contracts & Financial Management	
	Insurance and indemnity arrangements	
13.	Publication and dissemination policy	25
14.	References	26
15.	Appendices	30
	Patient invitation letter & screening question, Version, Dated	
	Participant information sheet Version, Dated	
	Consent form Version, Dated	
	Baseline, 7 day, 3 month & 12 month questionnaires Version ,Dated	
	Non-participant questionnaire, Version, Dated	
	Baseline & 12 month measurement sheets, Version, Dated	
	Instructions for 12 week walking programme, Version, Dated	

#### 1. Summary

Background: Physical activity is vital for health, yet most adults and older adults are inactive and do not achieve the recommended 30 minutes of moderate intensity activity on 5 or more days weekly. Moderate intensity activity makes you warm and increases breathing and heart rate, but should allow conversation. Adults' most common physical activity is walking, light intensity if strolling, moderate if brisker (5km/hr). Pedometers measure step-count and can increase walking, but most trials have had short term outcomes, have not separated out pedometer effects from other support and have reported only step-counts, not time spent at different physical activity intensities. This trial will investigate whether inactive patients aged 45-74 years can increase their physical activity by being given a pedometer with a diary and written guidelines and whether additional individual, tailored, support from a practice nurse increases any benefits.

**Design:** Primary care based 3-arm randomized controlled trial with 12 month follow-up and health economic & qualitative evaluations.

Participants: 993 inactive patients aged 45-74 years with no contraindications to increasing their moderate intensity PA will be recruited by postal invitation from 6 South West London general practices and randomly allocated into three groups. All participants will have their PA assessed objectively (step-count & time spent at different PA intensities) for 7 days at baseline, 3 months and 12 months by wearing an accelerometer(Actigraph GT3X Manufacturing Technology Inc) and a blinded pedometer, which give no patient feedback. They will also complete questionnaires and have anthropometric assessments.

Intervention: One intervention group (pedometer alone) will be posted out a pedometer (Yamax Digi-Walker SW-200) diary and written instructions for a 12-week pedometer-based walking programme, based on their own baseline blinded pedometer step-count. The second intervention group (pedometer plus support) will receive a pedometer and diary and three individually tailored PA consultations with a practice nurse. They will be supported to follow a 12-week pedometer-based walking programme, using strategies such as self-monitoring, goal-setting, boosting motivation and anticipation of set-backs. The control group will continue usual PA.

Main outcome measures in all groups after 12 months:

- 1. Change in average daily step-count (primary outcome measure, by accelerometry)
- **2.** Change in sedentary time and time spent in at least moderate intensity PA weekly (by accelerometry)
- **3.** Cost-effectiveness. Incremental cost of the intervention to the NHS and incremental cost per change in step-count and per quality adjusted life year.
- 4. Acceptability of the interventions.

#### 2. Background and rationale

Why is PA important and what are the guidelines for PA levels for adults and older adults?

Physical inactivity is extremely detrimental to health. It can lead to many important negative health consequences and to increased overall mortality<sup>1,2</sup>. Adults, including older adults, are advised to be active daily and over a week their activity should add up to at least 150 minutes (2 ½ hours) of moderate intensity activity in bouts of 10 minutes or more, for optimum health benefits. One effective way to achieve this is to do 30 minutes activity on at least 5 days a week<sup>1-3</sup>. Moderate intensity PA makes you warm and increases breathing and heart rate, but should allow talking. Regular walking is the commonest PA of adults and older adults and is specifically promoted as a near perfect exercise, even walking at a moderate pace of 3 miles/hr (5km/hr) expends sufficient energy to qualify as moderate intensity PA, but with very low risk of harm<sup>4</sup>. Faster walking speeds are associated with reduced mortality<sup>5</sup>. UK public health policy emphasises helping adults and older adults to increase their PA, particularly through walking<sup>6-8</sup>. Both adults and older

adults are also advised to minimise the amount of time spent being sedentary (sitting) for extended periods<sup>1</sup>.

#### How much PA do adults and older adults do?

Amongst adults aged 16 and over in England, 39% of men and 29% of women self-reported achieving the recommended PA levels. However, PA levels decrease considerably with age and only 20% and 17% of men and women aged 60-74 respectively reported achieving these levels<sup>9</sup> despite most of those older people not walking being able to do so<sup>10</sup>. Time spent being sedentary is also an important independent disease risk factor<sup>2</sup>; this increases with age from 45 years<sup>9</sup>. As well as variations by age and gender there are also differences by socioeconomic status and ethnic group. Both men and women from lower socioeconomic groups report significantly lower PA levels than those from higher groups<sup>9</sup>. Men and women from Indian, Pakistani, Bangladeshi and Chinese ethnic groups are significantly less likely to achieve recommended PA levels, whilst other groups (Black Caribbean, Black African and Irish) are not significantly different from the general population<sup>11</sup>. Walking is the main physical activity reported by adults and older adults, but since it is unreliably recalled<sup>12</sup>, surveys may overestimate PA levels. Objective measurement of PA levels using accelerometers in a sub-sample of the Health Survey for England found that only 5% of men and 4% of women aged 35-64 years and 5% men and 0% of women aged 65 or more achieved the recommended PA levels, a fraction of those self-reporting achieving them<sup>9</sup>.

#### Summary of benefits and risks of increasing PA.

What are the benefits for increasing physical activity levels? The Chief Medical Officers from the four home countries recently published a report on physical activity for health, which has drawn upon recent international large scale reviews of the evidence on the impact of physical activity and its relationship to health across the lifecourse. The following benefits for adults and older adults are described: reduced mortality; a reduced risk of over 20 diseases and conditions (including cardiovascular disease, diabetes, obesity, osteoporosis, several cancers, depression, dementia); reduced falls risk; and improved function, quality of life and emotional well-being<sup>1</sup>. Physical inactivity is the fourth leading risk factor for global mortality (accounting for 6% of deaths globally). This follows high blood pressure (13%), tobacco use (9%) and high blood glucose (6%), with obesity and overweight accounting for 5% of deaths<sup>13</sup>. Physical inactivity is fourth on the list, but it influences most of the other causes. These effects are of major importance to both individuals and society, with the annual direct cost of physical inactivity to the NHS across the UK recently estimated at £1.06 billion<sup>1</sup> based on five conditions specifically linked to inactivity. However, this figure represents a conservative estimate, as it excludes the cost of other diseases and health problems that affect many older people<sup>1</sup>. UK public health policy now has an emphasis on helping adults and older adults to increase their physical activity, particularly walking<sup>6,7;14</sup>.

What are the risks from increasing physical activity? Whilst there are risks for adults and older adults associated with regular physical activity, the risks of a sedentary lifestyle far exceed them<sup>2;15;16</sup>. Both the intensity of physical activity and its regularity need consideration when assessing risk. Violent, unaccustomed exercise is associated with a higher risk of myocardial infarction and death in the following 24 hours, but regular, vigorous exercise protects against such events<sup>17</sup>. Low intensity physical activity has the lowest injury risk, but moderate intensity physical activity has a better risk-to-benefit ratio and should be the goal for inactive adults and older adults<sup>16</sup>. Moderate intensity physical activity carries a low risk of injury<sup>18</sup>, the commonest adverse events are musculoskeletal injury or falls<sup>19</sup>. Walking appears to be very low risk and has been described as a near perfect exercise<sup>4</sup>. Screening all participants before taking part in physical activity programmes is no longer advocated, as there is a very low degree of risk for light to moderate intensity physical activity<sup>2;20</sup>. Ory et al reviewed adverse events from 11 diverse physical activity interventions including older people and patients with heart disease. Numerous adverse events occurred in sedentary, chronically ill, older populations, but very few were attributed to activity interventions. No serious study-related adverse events were reported, but some minor ones were (mainly musculoskeletal injuries)<sup>20</sup>. A more recent trial of a primary care nurse intervention in women aged 40-74 years, showed a

small but significant increase in falls and injuries<sup>21</sup>. This trial advised 30 minutes of brisk walking five days per week. An important safety feature of our study is that baseline physical activity is recorded objectively on all participants, enabling individualised goals starting from the participant's own baseline. This is in line with advice that before increasing physical activity, older adults in particular should have risk management strategies for prevention of activity-related injuries; the most important being to start with low intensity physical activity and increase intensity gradually, the "start-low-and-go-slow" approach<sup>15;16</sup>.

## How can adults and older adults increase their PA levels?

A Cochrane systematic review of 17 RCTs of PA interventions reported moderate positive short-term effects in middle age (only 4 studies included older people) but findings were limited by most studies using self-report measures in motivated volunteers<sup>22</sup>. Effective interventions for increasing PA explored factors associated with behavioural change, including beliefs about costs and benefits of PA<sup>23</sup>. The American College of Sports Medicine updated position stand on prescribing exercise concluded that exercise programs in diverse populations have been effective in promoting short-term increases in physical activity when they are based on health behaviour theoretical constructs, are individually tailored and use behavioural strategies such as goal setting, social support, reinforcement, problem solving and relapse prevention<sup>2</sup>. A critical review and a best practices statement on older peoples' PA interventions advised home rather than gym-based programmes and cognitive behavioural strategies (e.g. goal-setting, selfmonitoring, feedback, self-efficacy, support, relapse prevention training) rather than health education alone 16;24. These behaviour change techniques are emphasised in the NHS Health Trainer Handbook, based on evidence from a range of psychological methods and intended for NHS behaviour change programmes, with local adaptation<sup>25</sup>. Starting low, but gradually increasing to moderate intensity is promoted as best practice, with advice to incorporate interventions into the daily routine, eg walking and to monitor intensity for progression<sup>16</sup>. A recent systematic review of interventions to promote walking concluded that interventions tailored to people's needs, targeted at the most sedentary or at those most motivated to change and delivered at the level of the individual or household can encourage people to walk more, although the sustainability, generalisability and clinical benefits of many of these approaches are uncertain<sup>26</sup>.

What is the evidence that pedometers can help adults and older adults to increase their PA levels? Pedometers are small, relatively inexpensive devices, worn at the hip, that provide direct feedback on PA frequency, the number of steps walked per day (step-counts). In 2006 the National Institute of Health and Clinical excellence (NICE) produced guidance on the use of pedometers to increase the population's physical activity levels<sup>27</sup>. They used stringent inclusion criteria and included evidence from only four quality randomised controlled trials involving different target groups<sup>28-31</sup>. They concluded that the evidence for pedometer based interventions in increasing PA levels in the adult population was equivocal in both the short and longer term. Specifically, a lack of evidence was found on the effect of pedometers on overall PA levels, as an adjunct to other interventions, and on long term outcomes (no evidence was found which examined effectiveness at one year). They recommended that pedometer based interventions should only be endorsed if part of a properly designed and controlled research study to determine their effectiveness<sup>27</sup>. Two subsequent systematic reviews and meta-analyses have been published. The first was based on 26 studies (8 RCTs and 18 observational studies) and found pedometer users increased steps/day by 2491(1098-3885) and PA levels by 27%. There were also significant reductions in body mass index and systolic blood pressure<sup>32</sup>. The most recent review was based on 32 studies and found that the combined effect size was 0.68 (95% CI 0.55-0.81) translating to an average increase of 2000 steps in the intervention group, indicating that pedometers are useful motivational tools to increase physical activity<sup>33</sup>. Both reviews found that setting a step-goal and using a step diary were key motivational factors for increasing physical activity<sup>32;33</sup>. Several limitations of the reviews were recognised. Firstly, study sizes were relatively small (the largest RCT had 330 participants, but the majority had less than 50) and interventions were of relatively short duration (mainly 12 weeks or less), so whether changes were durable over the long term was undetermined. Secondly, because many studies included several components (eg pedometer and counselling) the independent contribution of these components was difficult to establish. Finally, the inclusion of older people and men in studies included in the reviews was very limited <sup>32;33</sup>. Some more recent studies have focused on older people, had larger samples and attempted to isolate the pedometer's effects. An American trial in 147 older people showed an increase of 1320 steps/day at 12 weeks <sup>34</sup>, but provided no longer term follow-up. A Scottish trial of 210 older women found that physical activity was increased at 3 months by a pedometer plus behaviour change intervention (BCI), but the provision of pedometers yielded no additional benefit to the BCI apart from reducing drop-outs, and increased physical activity was not sustained by 6 months <sup>35</sup>. Two other recent trials in high risk groups (cardiac patients n=65, and impaired glucose tolerance n=87) have shown sustained increases in step-count at 12 months <sup>36;37</sup>.

What is the evidence about different step goals with pedometer interventions and how do these relate to physical activity recommendations for adults?

Pedometer users who were given a step goal were significantly more likely to increase their steps than those without a step goal. However, no difference was found between the different step-goals set<sup>32</sup>. Broadly studies have set goals based on either a fixed target (eg 10,000 steps/day)<sup>38;39</sup> or on taking an individual's baseline target and advising incremental increases, either as a percentage increase or by a fixed number of extra steps per day. Those advocating a percentage increase have tended to suggest 5% increase per week<sup>34</sup>, 10% biweekly<sup>40</sup> or 20% monthly<sup>35</sup>. Those advocating a fixed number of extra steps per day have tried to develop step-based guidelines that fit with existing evidence based physical activity guidelines with their emphasis on 30 minutes of at least moderate intensity physical activity on 5 or more days per week<sup>41</sup>. There is evidence that despite some individual variation, moderate intensity walking appears approximately equal to at least 100 steps per minute 41,42. If this is multiplied by 30 minutes (typical daily recommendation) it produces a minimum of 3000 steps per day, that is best used as a guiding value, but these steps need to be taken over and above habitual activity (or baseline). Several studies have advocated adding in 3000 steps/day on most days per week, either increasing by this amount from the beginning<sup>36</sup> or by increasing in an incremental manner (starting with an extra 1500 steps/day initially and gradually increasing)<sup>43;44</sup> or increasing by 500 steps/day every 2 weeks<sup>37</sup>. All of these studies that have advised adding 3000 steps/day to baseline have produced significant improvements in step-counts at 3 months and two measured outcomes at 12 months and showed sustained improvements in stepcounts<sup>36;37</sup>, waist circumference<sup>36</sup> and fasting glucose levels<sup>37</sup>. Although there is no evidence at present to inform a moderate intensity cadence (steps/minute) in older adults, Tudor-Locke at al advocate using the adult cadence of 100 steps/minute in older adults (whilst recognising that this may be unobtainable for some individuals) and advising that the 30 minutes can be broken down into bouts of at least 10 minutes<sup>45</sup>. This is the model being used currently in a primary care trial of a walking intervention which aims to recruit 46 older people<sup>46</sup>.

## Could accelerometers be useful in a study designed to increase walking?

Accelerometers are also small activity monitors, worn in a similar way to pedometers, much more expensive, but able to provide a time-stamped record of both PA frequency (step-counts) and PA intensity (activity counts). They require computer analysis and therefore give no direct feedback to participants. They therefore function as blinded pedometers in objectively measuring baseline and outcome PA data, but have the additional advantage of being able to provide objective data on time spent in different levels of PA intensity, particularly time spent in at least moderate intensity activity and time spent in sedentary activity, two important public health outcomes. Pedometer studies that do not use accelerometers have relied on self-report measures to assess these outcomes. Accelerometers have been shown to be valid and acceptable to adults<sup>9;47</sup> and older adults<sup>9;48;49</sup>. Although accelerometers measure step-count and there is a strong correlation between step-counts measured on accelerometers and pedometers<sup>50;51</sup> pedometers usually underestimate step-counts relative to accelerometers, particularly at lower walking speeds, and one instrument's step-counts may not easily be substituted for the other at an individual level<sup>51</sup>. Thus, although we will use the accelerometer as the main outcome measure to assess change in both step-count

and time spent in different physical activity intensities, we will use the blinded pedometer to set the individual step-count targets for individuals.

What is known about the cost-effectiveness of promoting PA through pedometer programmes?

To our knowledge, no study has examined the cost-effectiveness of pedometer based interventions in the UK. Evidence that exists on economic evaluation of PA interventions tends to focus on behavioural and environmental interventions<sup>52-54</sup>. Recent systematic reviews that considered the economic outcomes of pedometer based interventions found no evidence <sup>55;56</sup>. This has partly been attributed to insufficient data on the effect of pedometers on PA<sup>57</sup>. However, one Australian study has recently modelled the cost-effectiveness of a community programme to encourage use of pedometers as a motivational tool to increase PA in an Australian cohort of people aged >14 years<sup>58</sup>. Using disability adjusted life years as the main outcome measures, the authors found the intervention to dominate the alternative of 'do-nothing' and be cost-saving. The different context for this analysis however, makes it difficult to relate this finding to decision making in the UK. We are also aware that the cost-effectiveness of any intervention depends on participation, and our own research<sup>59</sup> shows that the demand for sports and exercise is negatively associated with time (travel time) and money cost that vary by participation (e.g. entrance charge) and positively associated with money cost that does not vary by participation (e.g. membership fee) holding socio-economic and demographic factors constant.

#### What is primary care's role in promoting PA?

Primary care is accessible and offers continuity of care for adults and older adults, with many chronic diseases being an indication for increasing PA. Health professional PA advice in consultations is individually tailored<sup>60</sup> and has greater impact than other PA advice<sup>61</sup>. Primary care nurses have been shown to be effective at increasing physical activity, particularly walking, in this age group<sup>21</sup>. PA promotion by other routes for older adults in particular is messy & unlikely to be as effective 62. Recent guidance on prescribing exercise in primary care reinforces the importance of follow up to chart progress, set goals, solve problems and identify and use social support<sup>63</sup> this will be an important feature of the nurse physical activity consultations in this trial. NICE Public Health Intervention Guidance on PA found that brief interventions in primary care are cost-effective, these varied from basic advice to offering extended and individually tailored consultations to identify and motivate change in physical activity behaviour. NICE therefore recommends that all primary care practitioners should take the opportunity, whenever possible, to identify inactive adults and advise them to aim for 30 minutes of moderate intensity activity on 5 days of the week or more<sup>27</sup>. New NHS Health Checks rolled out by 2013, will include adults up to age 74 & will incorporate advice on increasing PA, often by primary care nurses<sup>64</sup>. Evaluation of the UK Step-O-Meter Programme, delivering pedometers through primary care, in combination with physical activity consultations, showed self-reported PA increases, but advised investigation with a RCT design<sup>43</sup>. To date, to our knowledge, no trials have assessed the effectiveness of pedometers in combination with primary care physical activity consultations, although a small (n=79) community based programme showed a significant effect of pedometers and physical activity consultations on step-counts at 12 weeks in middle aged adults<sup>44</sup> suggesting the value of this combined approach and this group are now conducting a small trial (n-46) with older primary care patients<sup>46</sup>.

*Policy relevance.* UK public health policy emphasises helping adults and older adults to increase their physical activity, particularly walking<sup>6;7;14</sup>. MoreActive4Life is the physical activity strand of the Change4Life programme, a society wide approach to encouraging people to eat well, move more and live longer<sup>8</sup>. New NHS Health Checks being rolled out by 2013, include adults up to age 74 & incorporate advice on increasing physical activity, often by primary care nurses<sup>64</sup>. These directives underline the importance of getting adults and older adults to be more active and confirm the timeliness of our research for examining effective ways to achieve this.

Theory on which the intervention is based and relevant pilot and preparatory work

The pedometer-based intervention is based on previous work cited above showing that pedometers are effective at increasing steps, but extending this to ensure that the study covers older adults, men, has a 12 month follow-up and is designed to examine separately the role of the pedometer and the role of support. The practice nurse physical activity consultations will use cognitive behavioural strategies (e.g. goal-setting, self-monitoring, feedback, building self-efficacy, encouraging social support, relapse prevention training etc). These techniques are emphasised in the NHS Health Trainer Handbook, based on evidence from a range of psychological methods and intended for NHS behaviour change programmes, with local adaptation<sup>25</sup>. We will adapt the NHS health trainer handbook for use in this trial by the nurses to focus specifically on physical activity and using pedometers. All of these techniques will be used as described by Abraham & Michie<sup>65</sup>. Relevant pilot and preparatory work includes observational work using pedometers and accelerometers in a primary care setting<sup>48</sup> and a trial developing the physical activity consultations and pedometer based walking intervention in a study with older primary care patients (PACE-Lift trial funded by Research for Patient Benefit, personal correspondence, Harris et al).

Population to be studied. The population to be studied will be inactive adults and older adults aged between 45-74 years who are registered with six different general practices in South West London, who can walk outside the home and who have no contraindications to increasing their moderate intensity physical activity levels. We are using a single item validated questionnaire measure of self-reported physical activity<sup>21</sup> to select inactive adults. Those reporting achieving the Chief Medical Officers' guidelines of at least 150 minutes of at least moderate intenstiy physical activity weekly<sup>1</sup> will be excluded.

#### Rationale

These findings suggest that there is a need for a large, adequately powered study based in primary care to test the effect of a pedometer based walking intervention, with and without nurse physical activity consultations to support the intervention. The study should include follow-up to one year and ensure that adequate numbers of men and older adults as well as individuals from diverse socio-economic and ethnic backgrounds are included. For greatest effect the intervention should use step-goals and diaries and the physical activity consultations should be based on cognitive behavioural strategies, such as those used in the NHS Health Trainer Handbook<sup>25</sup>. In order to objectively test the effectiveness of the intervention on important public health outcomes, such as time spent in sedentary activity and time spent in at least moderate intensity activity, accelerometer measurement of outcomes should be included. The study should include a qualitative assessment to explore the intervention's acceptability and reasons for dropout and durability of effects. An economic evaluation should be performed alongside the trial and the costs and benefits of the alternatives should be modelled beyond the end of the trial.

#### Statement of trial conduct

The trial will be conducted in compliance with the protocol, GCP and the relevant regulatory requirements.

## 3. Study objectives and purpose

#### **Research objectives**

**Primary objectives** - in inactive adults aged 45-74 years:

- To determine whether or not the simple provision by post of pedometers plus written instructions for a pedometer-based walking programme, can promote an increase in step-counts and time spent in at least moderate PA compared to control at 12 months (pedometer vs control);
- To determine whether or not tailored support from practice nurse PA consultations combined with a pedometer based walking programme can promote an increase in step-counts and time spent in at least moderate PA compared to control at 12 months (pedometer plus nurse support vs control);

- iii) To determine whether or not the addition of tailored support from practice nurse PA consultations to the pedometer based walking programme alone, can promote a worthwhile increase in any effect on step-counts and time spent in at least moderate PA at 12 months (pedometer plus nurse support vs pedometer);
- iv) To determine the cost-effectiveness of these alternative approaches to increasing PA levels at both 12 months and from a life time perspective from the viewpoint of the NHS, personal social services and participants;

#### Secondary objectives:

- To determine whether age groups, gender, taking part as a couple, socio-economic-demographic sub-groups, level of baseline PA and health status modify the effect of the intervention on increasing PA levels at 3 months and 12 months;
- To explore the intervention's acceptability to practice nurses and inactive adults, reasons for dropout and durability of effects, by qualitative interviews after 12 month follow-up and focus groups on study completion;
- iii) To assess the fidelity and quality of intervention implementation over time by evaluation of patient diary step-count goals and recorded step-counts for both intervention groups at 3 month assessment and number of recorded practice nurse contacts for nurse support group.

## 4. Study design

## Description of type of trial

3-arm primary care based randomised controlled trial with 12 month follow-up comparing the following: a control group (usual physical activity); pedometer & written instructions; pedometer & support (written instructions and brief individually tailored PA consultations with a practice nurse). Qualitative, process and economic evaluations will run parallel to the trial.

Schematic diagram of trial design, procedures and stages: See Consort flow diagram (page 14).

## Primary and secondary endpoints

#### Primary outcome

Change in average daily step-count, measured over 7 days, between baseline and 12 months assessed objectively by accelerometry (Actigraph GT3X Manufacturing Technology Inc, FI USA).

## Secondary outcomes (other main outcomes)

Change in time spent in i) at least moderate intensity physical activity and ii) sedentary physical activity between baseline and 12 months, measured over 7 days by accelerometry.

Change in average daily step-count, time spent in at least moderate physical activity and time spent sedentary measured over 7 days, between baseline and 3 months assessed objectively by accelerometry Cost-effectiveness. Incremental cost of the intervention to the NHS and incremental cost per change in step-count and per quality adjusted life year.

Acceptability of the interventions (qualitative interviews and focus groups)

## Other outcome measures:

- i) change in self-reported physical activity from the questionnaire (General Practice Physical Activity Questionnaire (GPPAQ) International Physical Activity Questionnaire (IPAQ)
- ii) change in other patient reported outcomes from the questionnaire (exercise self-efficacy, anxiety, depression, perceived health status including mood and pain (EuroQol 5D [EQ-5D])

- iii) change in anthropometric measurements (weight, body mass index, waist circumference, body fat, bio-impedence (Tanita scales)
- iv) adverse outcomes (data on falls, injuries, major cardiovascular disease events and deaths will be collected as part of safety monitoring for the trial, through participant and nurse reporting, questionnaires at 3 and 12 months and primary care records
- health service use number of and diagnoses for all primary care consultations during the 12 months
  of the trial, as well as any out of hours, A&E or in-patient attendances related to falls, injuries,
  fractures etc from computerised primary care records at the end of the study given participants'
  consent.

#### Qualitative outcomes

There will be a range of outcomes from qualitative interviews and focus groups for both participants and practice nurses involved in implementing the intervention. We will gain an in-depth understanding of the acceptability and challenges with the interventions for participants and practice nurses, as well as valuable insights into the factors influencing why people opt not to participate in the intervention.

Methods and timing for assessing, recording and analysis of outcomes: The RA will conduct all the primary outcome assessments at 12 months. The RA will arrange postal collection of questionnaire and accelerometer data at 3 months. Data entry and recording of accelerometer data will occur as soon as each accelerometer is returned, when data will be downloaded. Data entry of questionnaire data will occur as soon as possible after data collection at each time period. Analysis of outcome data will occur when data on all participants is collected.

#### Measures taken to minimise / avoid bias


Randomisation: Participants completing the baseline assessment (including returning the accelerometer with at least 5 complete days of recording) will be allocated to the trial groups by the RA using the PCTU internet randomisation service to ensure independence of the allocation. Randomisation will be at household level to avoid couple contamination, which could occur if a couple were allocated to different arms. See section 6: Study Procedures for full details.

Contamination: Contamination could occur between partners in the same household, we will minimise this by ensuring that if both are recruited they are allocated to the same group. Contamination could also occur in the control group if they seek their own way of increasing their physical activity and particularly if they obtain and use their own pedometer. The 12 month assessment will capture this information.

Outcome assessment: The RA will arrange all the outcome assessments at 3 months (postal) and 12 months (at the practice). Appointments for these will be booked in advance according to a protocol, taking into account holidays. The RA assessing outcomes will not be blinded to the participants' intervention status for pragmatic reasons only; the study is funded to support only two RA to carry out recruitment and follow-up simultaneously at 3 practices each. If two RAs were required to cover each practice in order to carry out different assessments we would require further RA support for the trial. However, primary and secondary outcome measures (as above) are objectively measured by accelerometry and do not rely on assessor interpretation. Physical measurements will also be assessed objectively e.g. weight & body fat assessment. Patient reported outcomes (e.g. exercise self-efficacy, anxiety and depression, perceived health status including mood and pain, EuroQol 5D (EQ-5D)) will be assessed by validated self-report instruments, minimising researcher bias.

Statistical analysis: The senior statistician (SK) will analyse the data blind to the treatment allocation of the participants.

## CONSORT flow diagram showing participant flow through each stage of the randomized trial (enrolment, intervention allocation, follow-up & data analysis).



#### 5. Participant selection

Inclusion criteria for practices: Inclusion criteria will be as follows: being a practice in one of the 6 PCTs in the South West London cluster with a combined list size >10,000; giving a commitment to participate over the duration of the study; having a practice nurse interested and with time to carry out the physical activity interventions and trial procedures; and the availability of a room for the research assistant to recruit participants and carry out baseline and follow-up assessments.

Participant inclusion criteria: Patients aged 45-74 years registered at one of the 6 general practices within the South West London cluster where the research is being undertaken, able to walk outside the home and with no contraindications to increasing their moderate intensity physical activity levels.

Participant exclusion criteria: The commissioning brief advocated a focus on inactive adults, in order to maximise the benefits of the intervention to individuals and the NHS. We are therefore using a single item validated questionnaire measure of self-reported physical activity<sup>21</sup> to select inactive adults. Those reporting achieving the Chief Medical Officers' guidelines of at least 150 minutes of at least moderate intensity physical activity weekly<sup>1</sup> will be excluded. We anticipate that there will be a few participants who will be found on subsequent baseline accelerometer assessment to be above this level of physical activity (our previous pilot work suggests this number will be small as most people tend to overestimate their physical activity levels). They will not be excluded from the study, as this is a pragmatic trial and if this intervention were to be rolled out, exclusion would be on the basis of the screening question alone. Other exclusions: (from pilot study & from ProAct65+66): living in a residential or nursing home; housebound; ≥3 falls in previous year or ≥1 fall in previous year requiring medical attention; terminal illness; dementia or significant cognitive impairment (unable to follow simple instructions); registered blind; new onset chest pain, myocardial infarction, coronary artery bypass graft or angioplasty within the last 3 months; medical or psychiatric condition which the GP considers excludes the patient (e.g. acute systemic illness such as pneumonia, acute rheumatoid arthritis, unstable or acute heart failure, significant neurological disease or impairment, unable to move about independently, psychotic illness). Pregnant women will also be excluded from the trial.

Recruitment of practices: General practices will be recruited from the Primary Care Research Network Greater London (PCRN-GL). PCRN-GL will help us to identify potential participant practices within the South West London cluster of 6 PCTs (Wandsworth, Sutton, Merton, Croydon, Kingston, Richmond) who fit the above practice inclusion criteria. Approaches by mailed invitation, telephone contact with practice managers and personal contact with local GPs and practice nurses will all be used as necessary to identify practices who may be interested in taking part. For ease of recruitment for research assistants and managing the trial we will ideally select the 6 practices as pairs of practices from 3 PCTs. Once we have a list of potentially interested practices we will select 6 (ideally as pairs from 3 PCTs) to include a range of socio-demographic factors (including targeting some practices with high numbers of ethnic minority patients) and geographical circumstances based on practice postcode index of multiple deprivation (IMD) scores (at least 1 practice from each quintile). The IMD score includes factors such as distance to services, crime rates and road traffic accident rates, which could influence likelihood of outdoor physical activity, as well as material deprivation measures.

## Recruitment of participants:

The number of patients aged 45-74 years will be recorded at each practice. Practice staff will search practice electronic primary health care records to identify patients aged 45-74, using Read codes supplied by researchers and local care home knowledge to exclude ineligible patients (as per exclusion criteria, see above). A list of potentially eligible patients will be created and ordered by household (ie if there are 2 members of a couple living at the same address who are both potentially eligible this will be a double household, if there is only one person potentially eligible this will be a single household). If there are more than two eligible people in the same household only two people will be selected, this will be two identifiable as a couple by name, or the two people closest in age to each other. A random number list will then be used to select the sample of households to be

approached after exclusions have been made. Initially a random sample of 400 households containing eligible patients will be selected at each practice, the list will be examined by practice GPs to ensure trial suitability. Patients in these households will then be mailed an individual invitation letter about the trial from the practice and a screening questionnaire to assess activity levels and any contraindications to increasing moderate intensity physical activity. (A single item validated questionnaire measure of self-reported PA<sup>21</sup> will be used to select inactive adults, those reporting achieving the Chief Medical Officers' recommended guidelines of at least 150 minutes of moderate intensity PA weekly will be excluded<sup>1</sup>). The participant information sheet giving more details about the study will be sent out with the patient invitation letter, it will make clear that if potential participants have any difficulties understanding, speaking or reading english they should bring a family member or friend with them to the appointment with the research assistant. The participant information sheet will be translated into different languages when practices indicate that this would be appropriate. The 400 households will be mailed out to in a staggered manner over the 3 months to avoid overwhelming the research assistants. Further random samples of households will be selected from the list at 3 monthly intervals until required numbers have been randomised (166 individuals in total to intervention and control groups in each practice). On the reply slip, those not wishing to take part in the trial will be asked about their willingness to fill in a questionnaire about their health, physical activity levels and reasons for not wanting to participate. Patients who agree to participate in the trial will be telephoned to arrange a baseline assessment at the practice with the research assistant. Two eligible people within a household will be invited together (or apart if they prefer). Eligibility will be confirmed and informed consent sought at the appointment with the research assistant.

Participant selection for the qualitative evaluation: This will run parallel to the trial and will focus upon three distinct groups. i) Trial 'non-participants' who agree to be interviewed, to explore factors influencing their decision not to participate. ii) Purposive samples of four groups of trial participants, after 12 month follow-up (including samples of those who did and did not increase their PA in each of the two intervention arms). The samples will reflect the range of socio-demographic characteristics of participants including ethnicity. iii) All PNs (maximum 12 if two part-time PNs per practice) will be invited to participate in semi-structured interviews focussing upon their evaluation of the interventions' acceptability and use in PA consultations. Interviewing with study participants will continue until no new themes are identified (approximately 75 are anticipated, 15 for the 'non-participants' and 15 for each of the four groups of trial participants). The qualitative research assistant will also run a focus group at each practice at the end of the trial made up of the practice nurses and the research assistant involved at that practice and a sample of trial participants willing to attend, again reflecting the range of socio-demographic characteristics of participants.

Participant withdrawal: Participants will be free to withdraw from the trial at any time and without giving a reason. Practice nurses can advise discontinuation if the intervention poses a hazard to the participant. In both cases, information that has already been collected on participants may still be used and they will be asked if they would be prepared to provide any further data on outcomes at 3 and 12 months (eg questionnaire, anthropometric measurements and / or PA monitoring). Participants who withdraw before they have been randomised will be replaced, those withdrawing or being withdrawn after randomisation will not be replaced.

## 6. Study procedures

## Obtaining informed consent from participants

The participants will receive a postal invitation to take part in the study accompanied by a patient information sheet summarising the main points of the trial. Those who are interested in participating will return the reply slip, which includes a single, simple screening question about their usual physical activity levels. The research assistant will telephone them to make an appointment, if they are suitable, or to explain why not, if they are unsuitable. The decision regarding participation in the study is entirely voluntary. At the appointment the research assistant will go through the patient information sheet with them and answer any questions that they have about the study. If they are happy to proceed they can sign the study consent form. Patients with dementia, cognitive impairment and learning difficulties will have been excluded from the study by the initial computer search and by the GP checking invitations before they are sent out. However, the research assistant seeking consent will be fully trained in the

ethical principles underpinning informed consent and will be able to assess capacity to consent. Participants who have difficulty understanding, speaking or reading English will have been asked to bring a family member or friend with them to the appointment with the research assistant. Copies of the participant information sheet translated into other languages will be available if the practices have indicated that this is appropriate. After obtaining informed consent the research assistant will then continue with the baseline assessment. Patients will have at least a week to reflect further on their participation in the study before they are randomized.

Randomisation procedure: Participants completing the baseline assessment (including returning the accelerometer with at least 5 complete days of recording) will be allocated to the trial groups by the RA using the PCTU internet randomisation service to ensure independence of the allocation. Randomisation will be at household level to avoid couple contamination, which could occur if a couple were allocated to different arms. Randomisation will take place after both members of the household have completed baseline assessment. Block randomisation will be used within practice with random sized blocks to ensure balance in the groups and an even workload for nurses. The RA will inform participants by telephone whether they have been allocated to one of the intervention groups or to the control group.

Baseline, 3 month & 12 month assessment (all participants see flow chart page 14)
Baseline assessment

i)Questionnaire measures – Socio-economic-demographic measures: self-reported ethnic group, self-reported occupation, household composition. Self-reported physical activity: modified Zutphen questionnaire. Health problems: self reported chronic diseases (e.g. heart disease, lung disease, arthritis, depression etc); disability<sup>67</sup>. Patient Reported Outcomes (PROs) (exercise self-efficacy<sup>68</sup>, anxiety and depression (Hospital Anxiety & Depression Scale), perceived health status including mood and pain (EuroQol 5D (EQ-5D)<sup>69</sup>, loneliness<sup>70</sup>. After the participants have worn the accelerometer for 7 days to measure their physical activity levels participants will be asked to complete a short questionnaire about self-reported PA in the last 7 days (General Practice Physical Activity Questionnaire (IPAQ)).

ii)Anthropometric measures – height; weight; waist circumference; hip circumference; body fat, bioimpedence (Tanita monitor);

iii) Objective PA assessment (patient blind to results) measurement of usual physical activity levels (wearing an accelerometer and a blinded pedometer on a belt over one hip, all day for 7 days, only removing for bathing). The monitors and belt will need to be dropped back into the practice after use. The Actigraph (GT3X Manufacturing Technology Inc., Fl. USA) measures vertical accelerations in magnitudes from 0.05-2.0g sampled at 30Hz then summed over a selected (5s) time period, it can record physical activity continuously for up to 21 days. The output, activity counts per unit of time, distinguishes between different walking speeds and physical activity intensities, using standard cut-offs<sup>48,49</sup>. The pedometer function on the accelerometer records steps and will be used for baseline and outcome measurment of step-counts for the trial. The blinded pedometer also records steps and will be used to set an individual step-count target for those randomised to an intervention group, as there can be individual differences in step-counts between the accelerometer and pedometer and participants in the intervention group will be using a pedometer to monitor their own step-counts.

3 month assessment (postal): As for baseline assessment, including accelerometer assessment of physical activity, but there is no anthropometric assessment and the questionnaire does not repeat socio-economic-demographic measures, but has additional questions about adverse events, including injuries and health problems over the past 3 months.

12 month assessment (at practice): As for baseline assessment (including anthropometric assessment and accelerometer assessment) but the questionnaire does not repeat socio-economic-demograhic measures, but has additional questions about adverse events, injuries and health problems over the past 12 months. The control group will additionally be asked about whether they have used a pedometer at any time over the last 12 months.

Procedure for control group (usual physical activity):

After baseline assessment and randomisation, the RA informs participants by telephone that they are in the usual physical activity group and that they should continue as usual with their physical activities throughout the trial. She

/he will thank them for participating and arrange the 3 month postal asssessment and the 12 month outcome assessment appointment at the practice, posting out an accelerometer to wear for the 7 days before these. The research assistant will also make contact at 6m & 9m (by telephone, text, email according to patient preference) to check on safety outcomes and contact details. On study completion, the control group will be offered a practice nurse PA consultation with advice on how to increase their physical activity levels and a pedometer to keep.

Nature of the complex intervention: 12 week pedometer-based walking intervention delivered either by post with written instructions or delivered in the context of 3 brief physical activity consultations with a practice nurse, based on a cognitive behavioural approach.

## Components of the complex intervention

## i)Pedometers

Yamax Digi-Walker SW-200 (Tokyo, Japan) is the criterion pedometer with best accuracy<sup>71-73</sup>. It provides direct step-count feedback to participants. Step-counts need daily manual recording and re-setting. The pedometer will be delivered by post along with written instructions on it's use to the pedometer group, it will be given by the nurse directly to patients in the pedometer plus support group.

ii) Written instructions and physical activity diaries for a 12-week pedometer based walking intervention (delivered by post to pedometer group, provided in consultations for pedometer plus nurse support group)

We will have participants' baseline step-count from their blinded pedometer assessment. They will be given feedback on this and information about the fact that adding in 3000 steps/day in 30 minutes on 5 or more days weekly to their baseline would help them to achieve the recommended daily physical activity guidelines and that this can be built up gradually. They will be given advice on the benefits of at least moderate intensity physical activity for health and informed that moderate intensity PA makes you feel warm and makes you feel a bit breathless and increases your heart rate, but that you should still be able to talk. A suggested walking plan will be provided as follows:

Weeks 1-2: Add in 1500 steps in 15 minutes 3 or more days per week

Weeks 3-4: Add in 1500 steps in 15 minutes 5 or more days per week

Weeks 5-6: Add in 3000 steps in 30 minutes (or 2 x 15 minute bouts) on 3 or more days per week

Weeks 7-8: Add in 3000 steps in 30 minutes (or 2 x 15 minute bouts) on 5 or more days per week

Weeks 9-12: Maintenance, continue adding on 3000 steps in 30 minutes on 5 or more days per week.

They will be given diaries for recording their daily step-count on so that they can see if they are acheiving their target for that week. They will be given written advice on how to maintain their activity, and how to anticipate and manage setbacks. Their will also be an optional website for those who wish to access it, where they can enter their step-counts for the week and it will automatically calculate their average daily step-count for each week of the trial and chart their progress.

*ii)Physical activity consultations with a practice nurse based on a cognitive behavioural approach* The cognitive behavioural model includes patient-led goal setting based on behaviour change principles, including motivational language, problem-solving, self-monitoring, 'SMART' goals, social support, relapse prevention, addressing barriers, use of written tools including diaries. These techniques have been successfully used by non-specialists in primary care after brief training<sup>74</sup> and are emphasized in the NHS Health Trainer Handbook<sup>75</sup>. Pedometer measurement and diary recording of step-counts provides clear material for physical activity goal-setting, self-monitoring and feedback and should fit very well with this approach. Practice nurse training in a cognitive behavioural approach to increasing PA based on the NHS Health Trainer handbook, combined with training in advising on a 12-week pedometer based walking intervention will be provided.

#### Procedure for the pedometer group

After baseline assessment and randomisation, the RA informs participants by telephone which group they have been allocated to and arranges to post out a pedometer with easy to follow written instructions for a 12 week pedometer-based walking programme. The 12 week programme is based on the participant's own baseline stepcount (as assessed by the accelerometer) and advises incremental step-count increases as outlined above. Participants will be given a simple diary to record daily and weekly step-count goals and daily step-counts. Written

advice on anticipating and managing setbacks and maintenance following the programme will also be provided. The RA will telephone 1 week after sending out the pedometer to check that it has arrived safely and that it is working properly and to offer a replacement pedometer in the event of loss or malfunction during the 12 week intervention. She will also check that participants understand the 12 week pedometer based walking plan and answer any questions that they have. Arrangements for 3 and 12 month assessments are as for the control group. The research assistant will also make contact at 6m & 9m (by telephone, text, email according to patient preference) to check on safety outcomes, contact details and progress and to offer support and motivation. On study completion, participants in this group will be offered a practice nurse PA consultation.

## Procedure for the pedometer plus practice nurse support group

After baseline assessment and randomisation, the RA informs participants by telephone that they are in this group and arranges an appointment for them with the practice nurse for their first physical activity consultation. The support package consists of a 12 week pedometer-based walking programme with 3 short individually tailored physical activity consultations with a practice nurse (week 1, week 5, week 9). Their baseline step-count (from their blinded pedometer recording) will be reviewed alongside health and anthropometric data, so that an individual physical activity plan, tailored to their baseline step-count abilities, health, goals and personal circumstances and based on increasing walking and walking speed and other existing physical activities, can be produced. At the first consultation the nurse will show participants how to use the pedometer to measure their step-count and how to record step-counts on a weekly diary. The written instructions for the 12 week pedometerbased walking intervention being used by the postal group will also be given to the patients in this group by the nurse, but there can also be individual discussion between the nurse and the patient about what level of stepcount increase is most appropriate for them and how fast to increase this. Participants will be asked to wear a pedometer and keep a diary record of daily steps for 4 weeks until they are seen at their next appointment when these will be reviewed with the nurse. If they have achieved their goals, new goals can be set, if not, then problems and barriers and ways of overcoming them can be discussed. Participants can be seen individually or as a couple, for couples both individual goals and opportunities to increase their PA together will be discussed. Arrangements for 3 and 12 month assessments are with the research assistant, as for the control group. The RA will also make contact at 6m & 9m (by telephone, text, email according to patient preference) to check on safety outcomes, contact details and progress and to offer support and motivation.

#### *Procedure for qualitative study:*

The qualitative researcher will approach the groups identified in section 5 (participant selection for the qualitative evaluation) and seek their informed consent for a semi-structured interview. He/she will also run a focus group at each practice a the end of the trial, made up of practice nurses and the research assistant involved at that practice and a sample of trial participants. For each group, all interviews will be audio-recorded (unless participants do not consent, when contemporaneous field notes will be taken) and transcribed verbatim professionally. Thematic analysis will proceed in parallel with the interviews to enable refinement of the interview guide and purposive sampling according to emerging themes.

#### Procedure for the health economic evaluation

The economic evaluation will take the perspective of the NHS, personal social services and participants and first undertake a trial based analysis. Participant-level resource use data will be collected for equipment (pedometers), face to face or telephone consultations (length of time and frequency), out of pocket expenses (e.g. transport costs), use of support services (number of calls and contacts by post) and for other health service use (e.g GP attendances, in-patient days, out-patient visits, home visits and services from social services, stays in nursing and residential care). Data will be collected through primary care records, participant questionnaire at 3 and 12 months and monitoring by nurses. Data collection procedures will be merged with effectiveness where possible. Costs that don't vary by use (e.g. development, production and translation of leaflets) will be costed separately and apportioned to patients within the relevant arm of the trial. Unit costs will be valued using national averages to increase their generalisability.

End of study definition: The end of the study for each participant in the nurse support group is when they have attended their 12 month assessment . For the other two groups (control and pedometer plus written instructions)

they will be offered a single physical activity consultation with the practice nurse after their 12 month assessment. If they accept this, the end of the study for them will be after this consultation. The end of the study overall is when all patients have completed their 12 month assessments and subsequent consultations with the nurses.

Participant withdrawal: If a participant withdraws after signing their informed consent but before completing their baseline assessment (including monitoring their physical activity for 7 days) and before randomisation, they will be replaced with a further participant. Any information already collected on them may still be used.

Data collection and follow-up for withdrawn subjects: Participants who withdraw from the trial will be asked if they would be prepared to contribute to further data collection on outcomes at 3 months and 12 months (eg questionnaire, anthropometric measurements and / or physical activity monitoring).

## 7. Safety

Risks: The PACE-UP study poses a low risk to patients' health and to the cause of any serious adverse events. Careful application of the exclusion criteria, from screening primary care records and involving both the GP and patient, will minimize the risk of adverse events. Additionally, the study is based in primary care and patients can discuss concerns with their GP; practice nurses will receive safety training; the intervention is low risk and based on increasing walking and other activities that they already do, not introducing new activities; and the intervention is individualised and starts from the participant's own baseline activity level with encouragement to start-low-and-go-slow, to minimize risks. However, the information sheets will inform participants and GPs of the potential injury risks, so that consent is obtained with prior knowledge.

Adverse events: An adverse event (AE) is any unfavourable and unintended sign, symptom or illness that develops or worsens during the period of observation of the trial. This includes:

- i) Exacerbation of a previous illness
- ii) Increase in frequency or intensity of a pre-existing episodic event or condition.
- iii) Condition detected after the study started even though it may have been present prior to the study.
- iv) Continuous persistent disease or symptoms present at baseline that worsen following the study start.

Serious adverse events: A serious adverse event (SAE) is any adverse event occurring following study mandated procedures, having received either of the physical activity interventions or usual treatment that results in any of the following outcomes:

- i) Death
- ii) A life-threatening adverse event
- iii) Inpatient hospitalization or prolongation of existing hospitalization
- iv) A disability / incapacity

Causality: Adverse and serious adverse events can be unrelated, unlikely to be related (non-attributable), possibly or probably related (indirectly attributable) or definitely related to the study (directly attributable). Death from chest infection is a serious non-attributable adverse event and fracture requiring hospitalization from a fall whilst walking is a serious indirectly attributable adverse event. The intervention groups will be asked to increase activities they were already doing, not to take up new ones, so physical activity related adverse events could have happened without them being in the trial, therefore in most cases will be indirectly attributable to the trial.

Notification and reporting of adverse events: A standard operating procedure for the management of adverse events will be in place, so that participants or their relatives, practice staff or researchers can inform the chief

investigator of any event they consider possibly related to PA promotion. All adverse events reported will be assessed for seriousness, expectedness and causality. All adverse events will be recorded and monitored until resolution, stabilisation or until it has been shown that the intervention is not the cause.

Notification and reporting of serious adverse events (SAE): Participants or relatives will be asked to contact the trial site immediately in the event of any SAE. The Chief Investigator shall be informed immediately and shall determine seriousness and causality in conjunction with any treating medical practitioners and another trial physician. SAE need to be reported to the patient's GP. If the CI determines that the SAE was not causally related to the study intervention then the SAE will go on the annual safety report and no further action is necessary. A serious adverse event that is deemed directly or indirectly attributable to the study intervention will be reported to the Ethics Committee, Trial Steering Committee, R&D department and study sponsor, within 15 days of the CI becoming aware of the event if it is not life-threatening or fatal and within 7 days if it is.

#### Retrospective data collection on adverse events:

*i)Questionnaires:* Intervention and control groups will be sent questionnaires at 3 months and 12 months that will ask specifically about falls, injuries and exacerbation of any pre-existing conditions in the previous 3 month and 9 month periods respectively.

*ii)* Contact with research assistant: The research assistant will contact participants in all 3 groups at 6 and 9 months (by telephone, text or email as preferred by participant) and will ask about adverse events since the last contact.

*ii)Computerised primary care records:* In order to be sure that full data on adverse events is collected, informed consent will be sought to collect data from participants records at the end of the study. All consultation data for the 12 month period of the study for each individual will be downloaded from practice computerised records, including all new problems recorded during this period. Additionally data on all hospital admissions, out of hours attendances and out patient appointments recorded will be downloaded. This will be anonymised before removal from the practice and a researcher who is blind to the intervention or control status of the participants will analyse this data with a standardised proforma recording possible adverse events.

Monitoring: Mechanisms will be set up for decision making and governance, with external judgment of the trial's safety; the Trial Steering Committee (TSC) will assess safety parameters. Precise details on reporting and decision making mechanisms will be agreed at the first TSC meetings, before patient recruitment.

Annual safety report:

The chief investigator must report all serious adverse events annually to the REC and the funder.

### 8. Statistics

#### Sample size:

A meta-analysis of a heterogeneous group of short-term intervention studies involving pedometers showed interventions increased steps count per day by 2500 with a SD of 2700<sup>32</sup>. However a smaller increase in steps of 1000 per day would lead to worthwhile health gains if this was sustained for 12 months. We also want to be able to demonstrate whether there are differences in the effects achieved by a pedometer intervention alone compared to a pedometer intervention with nurse support. A sample of 217 patients in each of 3 arms would allow a difference of 1000 steps per day to be detected between any two arms of the trial with a 90% power at the 1% significance level. This means that we will have sufficient power to adjust for multiple hypothesis testing. However, we plan to randomise households. For men and women the effect of clustering is likely to be small but needs to be taken into account when stratifying by age. Assuming an intracluster correlation of 0.5 and an average household size of 1.6 eligible patients we would need to analyse 282 patients per arm. Allowing for approximately 15% attrition we would need to randomise a total of 993 patients (331 control, 331 pedometer only and 331 pedometer plus nurse support). There are 6 general practices (centres) each will recruit approximately 166 patients, approximately 55 to each of the 3 groups.

## Anticipated recruitment:

We anticipate a conservative recruitment rate of 20% amongst those eligible to participate. This estimate is based on pilot work using pedometers and accelerometers in an observational study of older primary care patients, recruitment rate 43% and other studies of PA interventions (including with pedometers) amongst middle aged

and older adults in primary care, where recruitment has been between 17% and 35%<sup>35;76-79</sup>. Even if our recruitment rate were as low as 10% we would have enough eligible participants (see flow chart page 14).

## Statistical analysis:

All participants will be included in the primary analysis if they have at least 1 satisfactory day of accelerometer recording out of 7 days. A satisfactory recording comprises at least 600 minutes of registered time during a day. Adequacy of the randomisation process to achieve balanced groups will be checked by comparing participant characteristics in the 3 arms (e.g. age, sex, socio-economic group, baseline PA level, health status, body mass index, household size).

Estimates of difference between the treatment arms will be based on an analysis of variance model with change in step-count as the dependent variable and allowing for practice and household as random effects. All intervention arms will be compared with each other, adjusting for multiple comparisons. Any variables found to be unbalanced on the baseline analysis will be included in an adjusted analysis.

Subsidiary analysis will investigate whether there is any evidence of interaction, that is whether the treatment effect varies by the following factors: age (<60 versus >=60) gender, socio-economic group, ethnic group, participating as a couple.

A regression model will be used to assess whether change in step-count is related to compliance with the intervention, by including the number of nurse sessions attended (nurse intervention group) and whether or not individual step-count targets were set (nurse intervention group) as variables in the regression model. Numbers in each group who have suffered a fracture, falls and injuries and drop-outs will be compared between the groups using logistic regression in Stata adjusted for clustering.

Stopping rules: It would be impossible to carry out interim analyses on sufficient patients to decide to stop, so there are no formal statistical stopping rules. If a patient becomes ineligible, the nurse may discontinue the intervention, but all patients will be asked to complete follow-up assessments. Patients can withdraw at any time.

Procedure for accounting for missing, unused and unexpected data: Only days with >600 minutes of registered time on accelerometer on a given day will be used. Multi-level modeling will be used to allow for day of week of measurements. This will allow change within subjects to be estimated, even if less than 7 days of data is provided.

### 9. Data handling and record keeping

## Confidentiality and data protection:

Only members of the patient's existing clinical care team will have access to records to identify potential participants, check whether they meet the inclusion criteria and make the initial approach to patients. We will ensure that the approach to patients comes from their existing clinical care team. Invitation letter to patients will be sent out by practices from the practice premises. No details on participants will leave the practice until patient consent is given. Participants' personal data will remain confidential and will be handled, processed and destroyed in accordance with the terms of the Data Protection Act. Dr Tess Harris is the data custodian. Only nurses working in the practice, the research assistant and principal investigator employed by SGUL and authorized research monitors from the Primary Care Trust will have access to non-anonymised data. They are all bound by their organisations 'policies on data protection.

Personal contact details (eg addresses, telephone numbers and emails) and the code linking patient identity with their unique study ID numbers are particularly sensitive information and will not be stored on memory sticks or external hard drives. Paper copies will be kept in a locked filing cabinet in a locked office at the general practices. Electronic copies will be encrypted on a secure encrypted laptop and then transferred to and stored as encrypted files on a secure network drive at SGUL which is saved onto the UNIX system with regular secure back-ups. The encrypted files with personal contact details (eg name, address, contact details) will be kept on a separate drive of

the secure server at SGUL from files which are pseudo-anonymised (with an IDNO) and contain study details on respondents (eg height, weight, questionnaire responses).

All NHS computers, university computers and laptops will be password protected and files will further be further password protected to restrict to those who need access. All laptops and external hard drives used in the study (by the research assistants) will be strongly encrypted by processes at SGUL and files will be password protected. Data collected will be transferred from the laptops onto a secure network drive at SGUL, which is saved on the UNIX system with secure back-ups.

Individuals will be asked specifically about their consent for audio-recording individual qualitative interviews when they consent for the study. The audio-recordings will only be used for research purposes, specifically they will not be used for commercial purposes. Audio-recordings will be stored as digital files (with a unique identifier not a name) and backed up onto the secure SGUL network drive. Arrangements will be made for them to be securely accessed by the professional transcription service

Maintenance of study documents: A trial master file with essential documents containing information specific to each phase of the trial (before, during and after) will be kept in a Trial Master File in the Division of Population Health Sciences at St George's University of London. Site files to reflect the contents of the trial master file will be kept at each practice site.

Record retention & archiving: A copy of patient consent forms will be kept at each practice for 12 months after the study has ended before being destroyed. A paper copy of each patient consent form will be transferred to SGUL when patient recruitment has finished at that practice. The forms will be transferred by secure courier service. Personal data that is identified by patient name or address will be destroyed by 36 months after the study has ended. Other research data from the trial will be stored for 7 years after the study has ended at St George's University of London in the Division of Population Health Sciences & Education. Data will be stored on a secure area network drive, with password protected access restricted to members of the research team. Questionnaires will be archived in a secure locked archiving room. Electronic data will also be archived onto an encrypted external hard drive and stored with the archived questionnaires.

Digital recordings of interviews will be kept for 12 months after the study has ended (stored securely on the network drive at SGUL) and then will be destroyed. They will not be used for commercial purposes.

## 10. Ethics, compliance and clinical governance

Ethical considerations: The trial will be submitted for ethical review to one of the London Research Ethics Committees. The Trial Steering Committee (TSC) will provide overall trial supervision. The main ethical consideration is the risk of harm to participants (Section 7: Safety). Other ethical considerations are the way that recruitment and informed consent are handled, so that potential participants are not put under pressure to take part and the way that confidentiality is maintained (Section 5: Participant Selection, Section 6: Study Procedures & Section 9: Data Handling).

Compliance: The trial will be conducted in compliance with the protocol, Good Clinical Practice and regulatory requirements.

Clinical governance issues: National Health Service (NHS) Research & Development (R&D) approval will be sought from Primary Care Trusts (PCTs) in the South West London cluster to cover all the practice sites. The research assistants and trial manager will require NHS research passports and letters of access from the PCTs in order to have contact with patients. The PI will also require a letter of access from the PCTs in order to support work in the practices. (If PCTs are replaced with commissioning bodies during the process of the trial, responsibility for governance will be transferred to them).

## 11. Monitoring

## Summary Monitoring Plan

A clinical trial baseline risk assessment has been carried out and has informed the approach to and extent of monitoring, which is fully documented in the monitoring plan.

#### Trial Oversight Committees

Trial Management Group (TMG): TMG members will be TH (chief investigator) SK (statistician) DC (epidemiologist) Sunil Shah (Public health physician) and the trial manager. Meetings will be held monthly, minutes will be retained in the trial master file. The TMG will monitor all aspects of the conduct and progress of the trial, ensure the protocol is adhered to and take action as necessary to safeguard participants and the trial itself. There will be weekly RA supervision meetings by the trial manager, to ensure day-to-day trial management is on track. TH is the project manager with overall responsibility for ensuring timely achievement of milestones. The Pragmatic Clinical Trials Unit will provide advice and support to the TMG on aspects of the trial such as data collection, data storage and data monitoring procedures.

## Trial Investigators' Group (TIG):

This group will include all of the trial investigators, they have responsibility for the trial's conduct and will meet 6 monthly with the research assistants and trial manager to review the progress of the trial. Individual co-investigators are also available between meetings for advice on specific areas as required.

Trial Steering Committee: The Trial Steering Committee (TSC) will provide overall trial supervision and ensure that it is being conducted in accordance with Good Clinical Practice. They will monitor the trial progress, including recruitment, data completeness and losses to follow-up and ensure that there are no major deviations from the trial protocol, they will also assess safety parameters. Membership will include an independent chair, Professor Sarah Lewis (statistician, University of Nottingham), an independent member representing the clinical area under study, Professor Paul Little (academic general practitioner, University of Southampton), Mr Bob Laventure, physical activity adviser for the British Heart Foundation to represent the wider public perspective and users views, the Principal Investigator TH and the trial statistician SK. Members of the TSC will be formally appointed by the Health Technology Assessment Programme. The meetings schedule for the TSC and precise details on reporting and decision making mechanisms will be agreed at the first TSC meeting, ahead of patient recruitment. Minutes for TSC meetings will be kept in the trial master file. A Data Monitoring Committee (DMC) will not be required as it would not contribute to the trial, as the risks are low, recruitment and follow-up are over a short period, and it would be impossible to carry out interim analyses on sufficient patients to decide to stop the trial or modify the trial protocol. The TSC chair can convene a DMC if they feel it is required.

## Before the start of recruitment

TMG, investigator and TSC meetings to review the trial and procedures.

Site visits to review set-up, team understanding of trial procedures etc.

Training of trial manager, research assistants and practice nurses in all aspects of the trial protocol relevant to them.

Input from PCTU on data collection and data monitoring procedures.

## During the trial

TMG, investigator and TSC meetings to review trial protocol and procedures.

Site visits to review set-up, team understanding of trial procedures, check of essential documents, including signed consent forms etc.

Central data checks.

Recording and reporting of adverse events and serious adverse events (as detailed under section 7).

Input from PCTU on data collection and data monitoring procedures.

PCTU Quality Assurance manager will carry out an audit of the study every 12 months.

Supervision and support for the research assistants will be provided by the trial manager and chief investigator.

Supervision and support will be provided to the nurses from the RAs, trial manager and chief investigator. The fidelity and quality of the implementation of the intervention will be monitored by completion of a checklist for each consultation between nurse and patient and completion of a nurse patient alliance questionnaire at the end of each patient's intervention.

Supervision & quality control for the qualitative RA & evaluation from Professor Victor.

### At the end of the trial

Check computerized primary care records for adverse events (check accuracy & missing reports).

Site visits to review archiving of trial documents.

Transfer signed consent forms from each practice to coordinating centre (SGUL) using secure courier.

## Audit and inspection:

The trial documentation will be made available to auditors and inspectors representing the sponsor, host institution and regulatory authorities.

Essential documents containing information relating to each phase of the stud (before, during and after) will be kept in a trial master file.

#### 12. Finance and insurance

Contracts & Financial Management: The contract for delivery of the project will be placed with St George's University of London, they will arrange sub-contracts as appropriate with academic partners.

Insurance and indemnity arrangements: SGUL will be the sponsor for the trial as the main employer of the Chief Investigator Dr Harris. The practice nurses will have indemnity arrangements in place with their practices that cover their clinical duties with patients. There are no special compensation arrangements for the trial. If a patient is harmed during the research study there are no special compensation arrangements. If a patient is harmed and this is due to someone's negligence, they may have grounds for a legal action for compensation against St George's, University of London, but they may have to pay their legal costs. The normal NHS complaints mechanisms will still be available to them.

#### 13. Publication and dissemination policy

Stage 1 (this will occur whatever the results show):

Publish trial protocol and research findings (RCT, health economic evaluation, qualitative evaluation) in high impact factor peer reviewed journals (e.g. Lancet, British Medical Journal etc). Also present prior to publication as posters, parallel & possible plenary sessions at academic conferences (eg Society of Academic Primary Care, Society for Social Medicine etc). Results will also be fed back to participants, practice nurses, practices, the PCTs & other interested parties locally through newsletters & local meetings.

Stage 2 (this will depend upon whether or not both interventions are effective and cost-effective and differences between the interventions in these measures):

If the trial has been well conducted with fidelity of implementation and both interventions were ineffective, then this would be an extremely important negative finding to disseminate to the NHS both locally at practice and PCT level and centrally via NIHR mechanisms.

If the interventions were both effective then differences between them in both effectiveness and costeffectiveness need to be explored and discussed in terms of effects this could have for policy for the NHS and fed back to the NHS centrally via NIHR mechanisms.

#### 14. References

- (1) Department of Health. Start Active, Stay Active: A report on physical activity for health from the four home countries' Chief Medical Officers. 2011.
- (2) Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc* 2011; 43(7):1334-1359.
- (3) O'Donovan G, Blazevich AJ, Boreham C, Cooper AR, Crank H, Ekelund U et al. The ABC of Physical Activity for Health: a consensus statement from the British Association of Sport and Exercise Sciences. *J Sports Sci* 2010; 28(6):573-591.
- (4) Morris JN, Hardman AE. Walking to health. Sports Med 1997; 23(5):306-332.
- (5) Dumurgier J, Elbaz A, Ducimetiere P, Tavernier B, Alperovitch A, Tzourio C. Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study. *BMJ* 2009; 339:b4460.
- (6) Department of Health. Choosing Activity: a Physical Activity Plan. 2005.
- (7) National Institute for Health and Clinical Excellence. Mental wellbeing and older people. 2008. NICE Public Health Guidance 16.
- (8) Department of Health. Change4Life. 2009.
- (9) Joint Health Surveys Unit. Health Survey for England 2008 Physical activity & fitness. 2009. The NHS Information Centre for health & social care.
- (10) Simonsick EM, Guralnik JM, Volpato S, Balfour J, Fried LP. Just get out the door! Importance of walking outside the home for maintaining mobility: findings from the women's health and aging study. *J Am Geriatr Soc* 2005; 53(2):198-203.
- (11) National Centre for Social Research. Health Survey for England 2004. 2005. London, Department of Health.
- (12) Tudor-Locke CE, Myers AM. Challenges and opportunities for measuring physical activity in sedentary adults. *Sports Med* 2001; 31(2):91-100.
- (13) World Health Organisation. Global Recommendations on Physical Activity for Health. 2010.
- (14) Department of Health. Be active, be healthy: a plan for getting the nation moving. 2009. London.
- (15) Morey MC, Sullivan RJ, Jr. Medical assessment for health advocacy and practical strategies for exercise initiation. *Am J Prev Med* 2003; 25(3 Suppl 2):204-208.
- (16) Cress ME, Buchner DM, Prohaska T, Rimmer J, Brown M, Macera C et al. Best practices for physical activity programs and behavior counseling in older adult populations. *J Aging Phys Act* 2005; 13(1):61-74.
- (17) Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. *N Engl J Med* 1993; 329(23):1677-1683.

- (18) Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology and the Council on Nutrition, Physical Activity, and Metabolism. *Circulation* 2003; 107(24):3109-3116.
- (19) Hootman JM, Macera CA, Ainsworth BE, Martin M, Addy CL, Blair SN. Association among physical activity level, cardiorespiratory fitness, and risk of musculoskeletal injury. *Am J Epidemiol* 2001; 154(3):251-258.
- (20) Ory M, Resnick B, Jordan PJ, Coday M, Riebe D, Ewing GC et al. Screening, safety, and adverse events in physical activity interventions: collaborative experiences from the behavior change consortium. *Ann Behav Med* 2005; 29 Suppl:20-28.
- (21) Lawton BA, Rose SB, Elley CR, Dowell AC, Fenton A, Moyes SA. Exercise on prescription for women aged 40-74 recruited through primary care: two year randomised controlled trial. *BMJ* 2008; 337:a2509.
- (22) Hillsdon M, Foster C, Thorogood M. Interventions for promoting physical activity. *Cochrane Database Syst Rev* 2005;(1):CD003180.
- (23) Hillsdon M, Foster C, Cavill N, Crombie H, Naidoo B. The effectiveness of public health interventions for increasing physical activity among adults: a review of reviews. London: HAD; 2005.
- (24) King AC, Rejeski WJ, Buchner DM. Physical activity interventions targeting older adults. A critical review and recommendations. *Am J Prev Med* 1998; 15(4):316-333.
- (25) British Psychological Society. Improving Health: Changing Behaviour: NHS Health Trainer Handbook. 2008. London, Department of Health.
- (26) Ogilvie D, Foster CE, Rothnie H, Cavill N, Hamilton V, Fitzsimons CF et al. Interventions to promote walking: systematic review. *BMJ* 2007; 334(7605):1204.
- (27) National Institute for Health and Clinical Excellence. Four commonly used methods to increase physical activity: brief interventions in primary care, exercise referral schemes, pedometers and community based exercise programmes for walking and cycling. Public Health Inervention Guidance no.2. 2006.
- (28) Talbot LA, Gaines JM, Huynh TN, Metter EJ. A home-based pedometer-driven walking program to increase physical activity in older adults with osteoarthritis of the knee: a preliminary study. *J Am Geriatr Soc* 2003; 51(3):387-392.
- (29) Tudor-Locke C, Bell RC, Myers AM, Harris SB, Ecclestone NA, Lauzon N et al. Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes. *Int J Obes Relat Metab Disord* 2004; 28(1):113-119.
- (30) Moreau KL, Degarmo R, Langley J, McMahon C, Howley ET, Bassett DR, Jr. et al. Increasing daily walking lowers blood pressure in postmenopausal women. *Med Sci Sports Exerc* 2001; 33(11):1825-1831.
- (31) DuVall C, Dinger MK, Taylor EL, Bemben D. Minimal-contact physical activity interventions in women: a pilot study. *Am J Health Behav* 2004; 28(3):280-286.
- (32) Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R et al. Using pedometers to increase physical activity and improve health: a systematic review. *JAMA* 2007; 298(19):2296-2304.
- (33) Kang M, Marshall SJ, Barreira TV, Lee JO. Effect of pedometer-based physical activity interventions: a metaanalysis. *Res Q Exerc Sport* 2009; 80(3):648-655.

- (34) Croteau KA, Richeson NE, Farmer BC, Jones DB. Effect of a pedometer-based intervention on daily step counts of community-dwelling older adults. *Res Q Exerc Sport* 2007; 78(5):401-406.
- (35) McMurdo ME, Sugden J, Argo I, Boyle P, Johnston DW, Sniehotta FF et al. Do pedometers increase physical activity in sedentary older women? A randomized controlled trial. *J Am Geriatr Soc* 2010; 58(11):2099-2106.
- (36) Houle J, Doyon O, Vadeboncoeur N, Turbide G, Diaz A, Poirier P. Innovative program to increase physical activity following an acute coronary syndrome: randomized controlled trial. *Patient Educ Couns* 2011; 85(3):e237-e244.
- (37) Yates T, Davies M, Gorely T, Bull F, Khunti K. Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. *Diabetes Care* 2009; 32(8):1404-1410.
- (38) Schneider PL, Bassett DR, Jr., Thompson DL, Pronk NP, Bielak KM. Effects of a 10,000 steps per day goal in overweight adults. *Am J Health Promot* 2006; 21(2):85-89.
- (39) Lindberg R. Active living: on the road with the 10,000 Steps program. J Am Diet Assoc 2000; 100(8):878-879.
- (40) Prochaska JJ, Hall SM, Humfleet G, Munoz RF, Reus V, Gorecki J et al. Physical activity as a strategy for maintaining tobacco abstinence: a randomized trial. *Prev Med* 2008; 47(2):215-220.
- (41) Tudor-Locke C, Craig CL, Brown WJ, Clemes SA, De CK, Giles-Corti B et al. How many steps/day are enough? For adults. *Int J Behav Nutr Phys Act* 2011; 8:79.
- (42) Marshall SJ, Levy SS, Tudor-Locke CE, Kolkhorst FW, Wooten KM, Ji M et al. Translating physical activity recommendations into a pedometer-based step goal: 3000 steps in 30 minutes. *Am J Prev Med* 2009; 36(5):410-415.
- (43) McKay J, Wright A, Lowry R, Steele K, Ryde G, Mutrie N. Walking on prescription: the utility of a pedometer pack for increasing physical activity in primary care. *Patient Educ Couns* 2009; 76(1):71-76.
- (44) Baker G, Gray SR, Wright A, Fitzsimons C, Nimmo M, Lowry R et al. The effect of a pedometer-based community walking intervention "Walking for Wellbeing in the West" on physical activity levels and health outcomes: a 12-week randomized controlled trial. *Int J Behav Nutr Phys Act* 2008; 5(1):44.
- (45) Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De B, I et al. How many steps/day are enough? For older adults and special populations. *Int J Behav Nutr Phys Act* 2011; 8:80.
- (46) Macmillan F, Fitzsimons C, Black K, Granat MH, Grant MP, Grealy M et al. West End Walkers 65+: a randomised controlled trial of a primary care-based walking intervention for older adults: study rationale and design. *BMC Public Health* 2011; 11:120.
- (47) Ekelund U, Tingstrom P, Kamwendo K, Krantz M, Nylander E, Sjostrom M et al. The validity of the Computer Science and Applications activity monitor for use in coronary artery disease patients during level walking. *Clin Physiol Funct Imaging* 2002; 22(4):248-253.
- (48) Harris TJ, Owen CG, Victor CR, Adams R, Cook DG. What factors are associated with physical activity in older people, assessed objectively by accelerometry? *Br J Sports Med* 2009; 43(6):442-450.
- (49) Davis MG, Fox KR. Physical activity patterns assessed by accelerometry in older people. *Eur J Appl Physiol* 2006.

- (50) Harris TJ, Owen CG, Victor CR, Adams R, Ekelund U, Cook DG. A comparison of questionnaire, accelerometer, and pedometer: measures in older people. *Med Sci Sports Exerc* 2009; 41(7):1392-1402.
- (51) Tudor-Locke C, Ainsworth BE, Thompson RW, Matthews CE. Comparison of pedometer and accelerometer measures of free-living physical activity. *Med Sci Sports Exerc* 2002; 34(12):2045-2051.
- (52) Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. *Lancet* 2010; 376(9754):1775-1784.
- (53) Muller-Riemenschneider F, Reinhold T, Willich SN. Cost-effectiveness of interventions promoting physical activity. *Br J Sports Med* 2009; 43(1):70-76.
- (54) Roux L, Pratt M, Tengs TO, Yore MM, Yanagawa TL, Van Den BJ et al. Cost effectiveness of community-based physical activity interventions. *Am J Prev Med* 2008; 35(6):578-588.
- (55) NICE Public Health Collaborating Centre. A rapid review of the effectiveness of pedometer interventions to promote physical activity in adults. 2006.
- (56) Talib H, Sabirin J. Pedometer and acelerometer in assessing physical activity among children and adolescents. 2007. Malaysia, Health Technology Assessment Unit.
- (57) NICE. Modelling the cost-effectiveness of physical activity interventions. 2006. London, National Institute for Clinical Excellence.
- (58) Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a modelling study. *PLoS Med* 2009; 6(7):e1000110.
- (59) Anokye N, Pokhrel S, Buxton M, Fox-Rushby J. The demand for sports and exercise: results form an illustrative survey. *European Journal of Health Economics* 2010; Under review.
- (60) Brawley LR, Rejeski WJ, King AC. Promoting physical activity for older adults: the challenges for changing behavior. *Am J Prev Med* 2003; 25(3 Suppl 2):172-183.
- (61) Tai SS, Gould M, Iliffe S. Promoting healthy exercise among older people in general practice: issues in designing and evaluating therapeutic interventions.[see comment]. *British Journal of General Practice* 1997; 47(415):119-122.
- (62) Goodman C, Davies S, Tai SS, Dinan S, Iliffe S. Promoting older peoples' participation in activity, whose responsibility? A case study of the response of health, local government and voluntary organizations. *J Interprof Care* 2007; 21(5):515-528.
- (63) Khan KM, Weiler R, Blair SN. Prescribing exercise in primary care. BMJ 2011; 343:d4141.
- (64) NHS Health Checks Programme. Putting prevention first: NHS Health Checks: Vascular Risk Assessment and Management Best Practice Guidelines. 2009.
- (65) Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions. *Health Psychol* 2008; 27(3):379-387.
- (66) Iliffe S. Multi-centre cluster trial in primary care comparing a community group exercise programme with home based exercise and with usual care for people aged 65 and over. ISRCTN 43453770. 2008. Health Technology Assessment Project grant.

- (67) McGee MA, Johnson A, Kay D. The Medical Research Council Cognitive Functioning and Ageing Study (MRC CFAS). The description of activities of daily living in five centres in England and Wales. *Age & Ageing* 1998; 27:605-613.
- (68) Jette AM, Rooks D, Lachman M, Lin TH, Levenson C, Heislein D et al. Home-based resistance training: predictors of participation and adherence. *Gerontologist* 1998; 38(4):412-421.
- (69) Brooks R. EuroQol: the current state of play. Health Policy 1996; 37(1):53-72.
- (70) Tunstall J. Old and Alone. London: Routledge and Kegan; 1957.
- (71) Bassett DR, Jr., Ainsworth BE, Leggett SR, Mathien CA, Main JA, Hunter DC et al. Accuracy of five electronic pedometers for measuring distance walked. *Med Sci Sports Exerc* 1996; 28(8):1071-1077.
- (72) Schneider PL, Crouter SE, Bassett DR. Pedometer measures of free-living physical activity: comparison of 13 models. *Med Sci Sports Exerc* 2004; 36(2):331-335.
- (73) Le Masurier GC, Lee SM, Tudor-Locke C. Motion sensor accuracy under controlled and free-living conditions. *Med Sci Sports Exerc* 2004; 36(5):905-910.
- (74) David L. Using CBT in General Practice. The 10 minute consultation. Oxfordshire: Scion; 2006.
- (75) Bristish Psychological Society. Improving Health: Changing Behaviour: NHS Health Trainer Handbook. 2008.
- (76) Little P, Dorward M, Gralton S, Hammerton L, Pillinger J, White P et al. A randomised controlled trial of three pragmatic approaches to initiate increased physical activity in sedentary patients with risk factors for cardiovascular disease. *Br J Gen Pract* 2004; 54(500):189-195.
- (77) Stevens W, Hillsdon M, Thorogood M, McArdle D. Cost-effectiveness of a primary care based physical activity intervention in 45-74 year old men and women: a randomised controlled trial. *Br J Sports Med* 1998; 32(3):236-241.
- (78) Munro JF, Nicholl JP, Brazier JE, Davey R, Cochrane T. Cost effectiveness of a community based exercise programme in over 65 year olds: cluster randomised trial. *J Epidemiol Community Health* 2004; 58(12):1004-1010.
- (79) Sugden JA, Sniehotta FF, Donnan PT, Boyle P, Johnston DW, McMurdo ME. The feasibility of using pedometers and brief advice to increase activity in sedentary older women--a pilot study. *BMC Health Serv Res* 2008; 8:169.

#### 15. Appendices

Patient invitation letter & screening question, Version, Dated
Participant information sheet, Version, Dated
Consent form, Version, Dated
Baseline, 7 day, 3 month & 12 month questionnaires, Version, Dated
Non-participant questionnaire, Version, Dated
Baseline & 12 month measurement sheets, Version, Dated
Instructions for 12 week walking programme, Version, Dated.